This elevated expression correlates with adverse clinicopathological features, including advanced T and N stages, and is strongly associated with diminished overall survival, highlighting MZT2B’s robust prognostic utility in NSCLC patients. Here, MZT2B is linked to non-small cell lung carcinoma.